Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Aytu BioPharma (Nasdaq: AYTU) announced management will present at NobleCon21 — Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) announced management will present at NobleCon21 — Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL.
The presentation is scheduled for Wednesday, December 3, 2025 at 10:30 AM ET. A high-definition webcast will be posted the following day on the company website and on Noble Conference and Channelchek, with the webcast archived for 90 days. Management will hold one-on-one investor meetings; scheduling via Noble representatives or aytu@lythampartners.com.
Details
News Market Reaction – AYTU
On Nov 25, the first trading day after this news, AYTU closed 2.67% above the previous close.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
Management will be presenting on Wednesday, December 3rd at 10:30 a.m. Eastern time. A high-definition video webcast of the presentation will be available the following day on the Company's website (www.aytubio.com), and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website (www.nobleconference.com) and on Channelchek (www.channelchek.com), the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website and on Channelchek for 90 days following the event.
Management will also be conducting one-on-one meetings at the conference. Investors should contact their Noble representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com, to schedule one-on-one meetings.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.